RecruitingPhase 2Phase 3NCT07079735

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)

Sponsor

Columbia University

Enrollment

150 participants

Start Date

Sep 12, 2025

Study Type

INTERVENTIONAL

Conditions

Heart Transplant Infection CMV Viremia Heart Transplant Failure and Rejection

Summary

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two antiviral drugs — valganciclovir and letermovir — to see which is better at preventing infection with a common virus called cytomegalovirus (CMV) in people who have recently received a heart transplant. CMV can cause serious illness in transplant patients whose immune systems are suppressed. **You may be eligible if...** - You are 18 or older - You have recently received a heart transplant - You have not yet started a CMV prevention medication after your transplant **You may NOT be eligible if...** - You have had a known or suspected CMV infection in the past 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.